Equillium Inc (EQ) |
|
8.82 -0.15 (-1.67%)
|
08-13 16:00 |
|
Open: |
8.82 |
Pre. Close: |
8.97 |
|
High:
|
9.09 |
Low:
|
8.62 |
|
Volume:
|
332,818 |
Market Cap:
|
170M |
|
|
|
|
Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
9.094 - 9.155 |
9.155 - 9.206 |
|
Low:
|
8.506 - 8.564 |
8.564 - 8.612 |
|
Close:
|
8.734 - 8.829 |
8.829 - 8.908 |
|
Technical analysis |
as of: 2020-08-13 4:33:45 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 20.87  One year: 31.59 |
| Support: |
Support1: 3.02 Support2: 2.51 |
| Resistance: |
Resistance1: 17.87 Resistance2: 27.05 |
| Pivot: |
10.52  |
| Moving Average: |
MA(5): 9.49 MA(20): 11.23
MA(100): 5.13 MA(250): 4.48 |
| MACD: |
MACD(12,26): 0.24 Signal(9): 0.82 |
| Stochastic oscillator: |
%K(14,3): 9.32 %D(3): 10.01 |
| RSI: |
RSI(14): 46.45 |
| 52-week: |
High: 27.05 Low: 2.20 Change(%): 117.8 |
| Average Vol(K): |
3-Month: 271598 10-Days: 68848 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.EQ has closed above bottom band by 15.7%. Bollinger Bands are 2.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 13 Aug 2020
Equillium Announces Pricing of Public Offering of Common Stock - GlobeNewswire
Wed, 12 Aug 2020
Is Equillium Inc (EQ) The Right Choice in Biotechnology? - InvestorsObserver
Wed, 12 Aug 2020
The Unprecedented Rise of Equillium Inc. (NASDAQ:EQ) - The Oracle Dispatch
Wed, 12 Aug 2020
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights - GlobeNewswire
Tue, 11 Aug 2020
Equillium Inc. (EQ) Quarterly Performance is 212.11%: Here is the Surprise Factor - The InvestChronicle
Tue, 11 Aug 2020
Equillium Inc (EQ) Stock: Is It a Good Pick? - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NasdaqGS |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
18 |
| Shares Float (M) |
7 |
|
% Held by Insiders
|
63.33 |
|
% Held by Institutions
|
26.01 |
|
Shares Short (K)
|
11 |
|
Shares Short P. Month (K)
|
76 |
Stock Financials |
|
EPS
|
-1.580 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
2.060 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-30.9 |
|
Return on Equity (ttm)
|
-57.4 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-1.572 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-25 |
|
Levered Free Cash Flow (M)
|
-16 |
Stock Valuations |
|
PE Ratio
|
-5.58 |
|
PEG Ratio
|
|
|
Price to Book value
|
4.28 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-6.27 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
